Amyloid Precursor Protein (APP) Affects Global Protein Synthesis in Dividing Human Cells

ANNA SOBOL, PAOLA GALLUZZO, SHUANG LIANG, BRITTANY RAMBO, SYLVIA SKUCHA, MEGAN J. WEBER, SARA ALANI, AND MAURIZIO BOCCHETTA*

Department of Pathology, Oncology Institute, Loyola University Chicago Medical Center, Maywood, Illinois

Hypoxic non-small cell lung cancer (NSCLC) is dependent on Notch-1 signaling for survival. Targeting Notch-1 by means of γ-secretase inhibitors (GSI) proved effective in killing hypoxic NSCLC. Post-mortem analysis of GSI-treated, NSCLC-burdened mice suggested that APP downregulation and Mechanistic Target of Rapamycin (mTORC-1) inhibition affected 4E-BP1 phosphorylation and global protein synthesis in opposite fashions. Additional investigations indicated that APP operates independently of mTORC-1. Key phenomena described in this study were reversed by overexpression of the APP C-terminal domain. The presented data suggest that APP may be a novel regulator of protein synthesis in dividing human cells, both cancerous and primary. Furthermore, APP appears to affect translation initiation using mechanisms seemingly dissimilar to mTORC-1 regulation of cap-dependent protein synthesis.

J. Cell. Physiol. 230: 1064–1074, 2015. © 2014 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.

Cell growth and proliferation are highly coordinated processes. A large amount of evidence supports a pivotal role for the phosphatidylinositol 3-OH kinase (PI3K)/Akt/mTORC-1 axis in the establishment of such a crosstalk. Studies showed that mutating several components of this signaling pathway influences both cell size and number, hence affecting organ size (Böhni et al., 1996; Leevers et al., 1996; Goberdhan et al., 1999). Likewise, inactivating mutations of genes leading to deregulated mTORC-1 activity and failed metabolic checkpoints cause syndromes characterized by multiple, tumor-like outgrowths in humans, such as Cowden syndrome (Liaw et al., 1997) and tuberous sclerosis (Brook-Carter et al., 1994). Conversely, experimental knockout of a number of genes involved in PI3K activation and its downstream effectors causes organ hypoplasia and reduced body size in mice (Liu et al., 1993; Dummler et al., 2006). mTORC-1 is a pivotal sensor of nutrient availability and stress conditions (Ellisen, 2005; Gwinn et al., 2008; Saqcena et al., 2013). In stress conditions the cell is generally under a dominant metabolic checkpoint that follows different mechanisms according to the severity and duration of such stimuli. Acute stress generally triggers phosphorylative inactivation of eIF-2A and rapid translational reprogramming (Spriggs et al., 2010), while chronic stress usually leads to repression of mTORC-1 activity through a number of mechanisms. The latter situation results in reduced 4E-BP1 phosphorylation at a number of residues (T70, S65, T37/46) (Gingras et al., 2001). Hypophosphorylated 4E-BPs sequester eIF-4E in a conformation that prevents its association with eIF-4G and ultimately the formation of a productive eIF-4F assembly on the 5′-end mRNA cap. In these conditions global protein synthesis is consequently suppressed. In conditions of severe hypoxia and nutrient deprivation (a typical situation in a hypoxic tumor microenvironment), inhibited mTORC-1 activity is unable to prevent the formation of the autophagosome, a process mediated by hypophosphorylated ATG13 (Hosokawa et al., 2009).

In several solid tumors, including NSCLC, hypoxic tissues require Notch signaling for survival or for hypoxia-induced proliferation (Chen et al., 2007; Eliaasz et al., 2010; Xing et al., 2011; Zou et al., 2013). In a previous study we found that Notch inhibition through administration of γ-secretase inhibitors (GSI) can target hypoxic NSCLC specifically, thus reducing its volume and related markers in an orthotopic NSCLC model (Liang et al., 2012). The γ-secretase complex cleaves a number of different proteins in their transmembrane domain (Hemming et al., 2008). There is no stringent sequence or site specificity for cleavage, and the intracellular domain that results from γ-secretase cleavage seems predominantly determined by the stability of the cleavage product according
to the N-end rule (Bachmair et al., 1986). Among the most studied γ-secretase substrates is the Amyloid Precursor Protein, or APP. APP is an extremely pleiotropic, single pass transmembrane protein involved in numerous cellular functions, none of which are definitively considered to be APP’s main role (Müller and Zheng, 2012). Its overall structure and cleavage pattern (ADAM10 and γ-secretase sequential cleavage) are reminiscent of Notch receptors, although the APP intracellular domain (AICD) is much smaller compared to Notch proteins (~6kDa). Currently, it is unclear whether APP (which is ubiquitously expressed as multiple splice variants, all of which undergo extensive post-translational modification) is a receptor or a ligand. It has two homologues, APLP-1 and APLP-2. APP has been linked to intra/extracellular matrix interactions, axonal functions, iron transport, and cytoskeleton communications. Some soluble, extracellular portions (APPSα) seem to have growth factor-like properties, while AICD seems to affect transcription (alongside cofactor Fe65) after its recruitment to membrane-bound APP. Cleavage of APP generates an AICD/Fe65 complex that translocates to the nucleus, where it affects transcription alongside factor Tip60 (Cao and Südhof, 2004). However, it is important to underscore that the mechanisms through which AICD can regulate transcription are still opaque (Beckett et al., 2012).

A few studies have implicated APP in tumorigenesis. More specifically, APP seems to promote cell growth through activation of extracellular signal-regulated protein kinase (ERK), an event also observed in neuronal cells (Nizzari et al., 2007). Additionally, APP, or its fragments, appears to interact with Akt signaling (Lee et al., 2009).

This study tests the hypothesis that γ-secretase inhibition could re-induce mTORC-1 activity in a quiescent hypoxic tumor environment. In vitro studies disproved this hypothesis and unexpectedly evidenced a role for APP in regulating protein synthesis independently of mTORC-1.

Materials and Methods

Unless otherwise specified, all studies are shown 48 h after experimental manipulation. Lists of siRNAs, antibodies and oligonucleotides used in this study are reported in Supplementary Material Table S1, Table S2, and Table S3, respectively.

Rationale of APP silencing

In the experiments shown here we used three different siRNAs against APP: one from Santa Cruz Biotechnology; Santa Cruz, CA (sc-29677), and two from Qiagen (Valencia, CA), referred to as siRNA9 (# SI02780281) and siRNA10 (# SI02780288). Both the Santa Cruz Biotechnology and the Qiagen siRNA10 were effective in downregulating APP, and primary experiments were performed using sc-29677 or SI02780288 indifferently. Since APP has ten putative splice variants, siRNAs potentially targeting different splice variants to different extents show occasional lack of reproducibility. The Qiagen siRNA10 targets the common 3'-end common to all splice variants and equally downregulates all of them. siRNA9 was not effective in sufficiently reducing either the APP mRNA or protein expression levels. Some experiments performed here were confirmed using shRNAs to APP cloned in pLKO.1 (#TRCN0000011043 and #TRCN0000006707, Sigma-Aldrich, St. Louis, MO). We provide a detailed representative downregulation experiment for APP in Figure 2B and C. We routinely confirmed APP downregulation in all experiments. Blots are omitted from figures to avoid unnecessary redundancy.

Chemicals and plasmids

γ-secretase inhibitor MRK-003 was a gift of Merck & Co. (Whitehouse Station, NJ). 5 µM MRK-003 was used in most experiments; exceptions are reported in figures and/or legends. Torin 1 (1-[4-[4-(1-Oxopropyl)-1-piperazinyl]-3-(trifluoromethyl) phenyl]-9-(3-quinolinyl)-benzo[h]-1,6-naphthyridin-2(1H)-one) (Tocris Bioscience, Bristol, UK) was dissolved in DMSO and used at a final concentration of 0.250 µM. Roscovitine (Cell Signaling) was dissolved in DMSO and used at a final concentration of 20 µM. UO126 (Selleck Chemicals, Huston, TX) was dissolved in DMSO, and used at a final concentration of 10 µM. Silvestrol (Medchemexpress LLC, Princeton, NJ) was dissolved in DMSO and used at a final concentration of 0.04 µM and 0.1 µM. Homoharringtonine (Tocris) was dissolved in DMSO and used at a final concentration of 0.1 µM. Insulin in solution (Sigma–Aldrich) was diluted in sterile PBS and used at the specified concentrations.

pcDNA3-RLUC-POLIRES-FLUC was a gift from Nahum Sonenberg (McGill University, Montreal); pCafen-MCSI-EF1-cop GFP expressing the APP C-terminal S9 aa was a gift from Dr. Xiao Z.C. (Institute of Molecular and Cell Biology, Singapore); full length APP 695 in pCAX vector was from Addgene (Cambridge, MA). We used the empty plasmids as transfection controls.

In vivo studies

The Loyola Institutional Animal Care and User Committee approved all studies. NOD.CB17-Prkdcscid/J mice (Jackson Laboratories, USA) were injected via the lateral tail vein with NSCLC cell lines. Details of mouse models and treatments are reported elsewhere (Eliaz et al., 2010).

Cell culture and transfection

A549, H1299, H1650, H1437, and WI38 were from ATCC (Manassas, VA). Me16 were a gift from Dr. Harvey I. Pass (New York University). HaCaT cells were provided by Dr. Mitchel Denning (Loyola University Chicago). Cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) under 0.5% O2, 5.0% CO2, 94.5% N2 in a Coy CleanSpect glove-box incubator (Coy Laboratory Products, Grass Lake, MI). Transfection of siRNA was performed using electroporation as previously described (Chen et al., 2007). Transfection of DNA was performed primarily using electroporation, or Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following the manufacturer protocols. Cell lines and cultures were fingerprinted using the GenePrint fluorescent STR system (Promega, Madison, WI). Absence of mycoplasma contamination was monitored using the MycoSensor QPCR assay kit (Stratagene, La Jolla, CA).

Antibodies and protein analysis

Western blot analysis was performed as previously described (Chen et al., 2007). The amount of total cell lysate loaded was experimentally determined to establish a linear range for the assay for each protein assayed (from 5 to 50 µg total cell lysate). Whenever possible, transfer nitrocellulose membranes were sliced according to suitable molecular weight ranges and simultaneously hybridized with different antibodies to reduce artifacts deriving from multiple stripping of primary antibodies procedures. Immunoprecipitations were performed according to manufacturer protocols. Lysates were incubated with specific primary antibodies at the concentrations recommended by manufacturers overnight at 4°C, followed by 1 h incubation with Protein A/G Magnetic Beads (Thermo Fisher Scientific Inc., Waltham, MA). After elution, proteins were resolved by SDS-PAGE, and transferred to Hybond-C membranes (Amersham, Cleveland, OH).

Immunofluorescence was performed as previously described (Eliaz et al., 2010) on either 8 µm-thick, flash frozen tissue slides or on cells seeded in glass immunochemistry slides. Primary antibody concentrations were optimized in pilot experiments. Secondary antibodies were conjugated with either Alexa Fluor 488 or Alexa Fluor 568. For tissue slides, autofluorescence was
quenched using the sodium borohydride protocol (http://www.uab.edu/highresolutionimaging/autofluorescence). Nuclei were visualized using DAPI staining. The Golgi apparatus was visualized using rhodamine labeled wheat germ agglutinin (Vector Laboratories, Burlingame, CA). Slides were mounted using fluorescence mounting medium (Dako, Troy, MI). Images were acquired at room temperature using EVOS FL Cell Imaging System (Life Technologies Corp., Carlsbad, CA).

**Cap binding assay and rate of global protein synthesis**

Cap binding assay was performed 48 and 72 h after transfection with control siRNA or siRNA against APP as previously described (Villalonga et al., 2009). Cells were lysed and incubated with either m7-GTP-Sepharose 4B beads (GE Healthcare, Cleveland, OH) or with unmodified Sepharose 4B beads (negative control).

The rate of global protein synthesis was measured using the Click-IT AHA Protein Synthesis Kit (Invitrogen) according to the manufacturer’s instruction. The incorporation of AHA was analyzed using a BD FACS Canto II instrument (Becton Dickinson, Franklin lakes, NJ). Flow cytometry data was analyzed by FlowJo software.

For AHA incorporation in the presence or absence of silvestrol or homoharringtonine, NSCLC cells were electrophorated with siRNA control or siRNA against APP (siAPP), plated in RPMI media supplemented with 10% FBS and allowed to attach overnight. After 36 h, the medium was changed to medium without methionine, supplemented with 1% FBS. 12 h later (48 h after transfection), cells were treated with either 0.04 μM or 0.1 μM of silvestrol, 0.1 μM homoharringtonine or vehicle (DMSO). Silvestrol, homoharringtonine or DMSO was added alongside AHA for 20, 30 or 40 min. In experiments performed with Torin-1, the compound was added at a concentration of 0.250 μM, the medium was replaced with fresh medium containing 0.250 μM Torin-1 after 24 h, and cells were analyzed 48 h after the original addition of Torin-1. After incubation, cells were detached, processed, washed, and examined by flow cytometry. In parallel, protein expression levels were determined by immunoblot. Each experiment was performed at least in triplicate.

**Gene expression analysis**

Total RNA was extracted using the RNeasy Mini kit (Qiagen). RNA concentration was determined using a NanoDrop Spectrophotometer (Thermo Fisher Scientific Inc.) and 1 μg of total RNA was used for cDNA synthesis. cDNA synthesis was performed using iScript Reverse Transcription Supermix RT-qPCR (Bio-Rad, Hercules, CA). Quantitative real-time PCR was done with SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) in an ABI 7300 thermal cycler (Applied Biosystems, Carlsbad, CA). Gene expression analysis was performed using the HumanHT12 (48,000 probes, RefSeq plus EST) array. Data was analyzed using Genome Studio software (Illumina). Only changes of ≥2-fold or more in gene expression common to the two cell lines were taken into consideration. These changes were confirmed using Q-PCR.

**Results**

**γ-secretase inhibition causes changes in 4E-BP1 phosphorylation pattern**

A hypoxic tumor microenvironment is traditionally considered to be resistant to radio/chemotherapy because cancer cells deprived of oxygen and nutrients are quiescent compared to well-oxygenated tumor tissue (Kyle et al., 2012). In previous studies, we targeted hypoxic tumor tissue in experimental, orthotopic NSCLC models using γ-secretase inhibitors in order to inhibit Notch-1 signaling (Chen et al., 2007; Eliasz et al., 2010; Liang et al., 2012). γ-secretase treatment proved effective in specifically killing hypoxic NSCLC, reducing its overall volume, increasing median survival, and reducing expression of hypoxia markers in NSCLC biopsies (Liang et al., 2012). In immunofluorescence studies, we used glucose transporter 1 (GLUT-1) as a marker of hypoxia because this protein’s overexpression is a reliable indicator of hypoxic cells and is perfectly co-expressed alongside hypoxia inducible factor (HIF-1α) (Eliasz et al., 2010). In vivo BrdU incorporation experiments and Ki67 staining confirmed that hypoxic tumor masses were essentially non-proliferating (Fig. 1A). mTORC-1 activation is generally considered to be an indication of active protein synthesis and cell cycle progression; one activation marker is phosphorylation of 4E-BP1 at T37/46 (Villalonga et al., 2009). Similar to what was obtained with BrdU incorporation or with Ki67 immunofluorescence experiments, hypoxic tumor regions did not show detectable 4E-BP1 phosphorylation at T37/46, while in tumor regions not expressing the hypoxia marker GLUT-1, phosphorylation was readily detectable (Fig. 1B). Post-mortem analyses of γ-secretase inhibitor (GSI)-treated mice revealed the presence of 4E-BP1 phosphorylated at T37/46 in tumor regions also displaying the hypoxia marker GLUT-1 (Fig. 1C). This data prompted the hypothesis that GSI treatment could have induced mTORC-1 activity in hypoxic tumors. We sought to test this hypothesis in vitro, but re-creating in vitro the conditions found in hypoxic tumor tissue is likely impossible, due to its intrinsic heterogeneity and complexity (Palmer et al., 2010). For this reason, we performed tissue culture experiments in complete medium, but preserved HIF-1α expression in our cells by culturing them under a 0.5% O2, 5.0% CO2, 94.5% N2 atmosphere. In such conditions, cells are not growth or proliferation arrested. Furthermore, at these O2 concentrations, mitochondrial functions are not compromised (Höckel and Vaupel, 2001), hence 0.5% O2 is not necessarily considered deep hypoxia. Higher oxygen concentrations did not reliably stabilize HIF-1α (not shown)

In vitro treatment of different NSCLC cell lines with GSI produced a marked increase of 4E-BP1 phosphorylation at T37/46 accompanied by an increase in steady state levels of total 4E-BP1 in one cell line (Fig. 1D; in other cell lines we observed collapsing of the three 4E-BP1 phosphorylated isoforms within the fastest migrating one). However, the 4E-BP1 mRNA expression levels did not significantly change (Fig. 1E). Considering that γ-secretase affects a plethora of substrates (Hemming et al., 2008) and that some GSIs seem to inhibit the proteasome (Clementz and Osipo, 2009), we sought to better determine the role of γ-secretase by artificially downregulating presenilin-1 and nicastrin (two critical components of the γ-secretase complex). Under these conditions of downregulation, siRNA to presenilin-1 and nicastrin caused an increase in T37/46 phosphorylation with no effects on the 4E-BP1 steady-state expression levels (Fig. 1F). Since artificial downregulation of γ-secretase complexes reproduced the effects of GSI exposure on 4E-BP1 phosphorylation at T37/46, we did not perform further experiments with GSI, which can target multiple cellular phenomena.

**APP is the γ-secretase substrate responsible for altered 4E-BP1 phosphorylation pattern**

Next we focused on the identification of the putative γ-secretase substrate(s) responsible for the enhanced 4E-BP1 phosphorylation. We first investigated Notch receptors, since
Notch-1 affects Akt activation in hypoxia (Eliasz et al., 2010). Artificial downregulation or forced Notch-1 through -4 intracellular domain expression yielded marginal and poorly reproducible results (not shown). This suggested that Notch receptors have little or no influence on 4E-BP1 T37/46 phosphorylation in our system. Next, we investigated another γ-secretase substrate, APP. Using different siRNAs, we determined that APP downregulation caused increased 4E-BP1 phosphorylation at T37/46 in different NSCLC cell lines, while overexpression of the APP intracellular domain, or AICD, produced the opposite effect (Fig. 2A; a representative APP downregulation experiment is shown in Fig. 2B,C, while the rationale for siRNA selection/usage is reported in Materials and Methods). When we genetically altered APP expression, we did not observe variations in the steady state total 4E-BP1 phosphorylation levels within the same cell line. This reinforces the idea that increased total 4E-BP1 expression upon GSI treatment in certain cell lines was due to γ-secretase inhibition (which affects about 91 cellular proteins) and possible off target effects of GSIs. APP appeared to be actively cleaved in NSCLC cells, as GSI treatment led to a dose-dependent accumulation of total APP (Fig. 2D), similar to what was observed for Notch-1 in the same cells (Chen et al., 2007). Further examination of the overall 4E-BP1 phosphorylation status after APP downregulation revealed decreased phosphorylation at S65 and unchanged phosphorylation at T70 (Fig. 2E). Previous studies have suggested that APP can influence ERK and/or Akt activation (Nizzari et al., 2007; Lee et al., 2009). We observed decreased ERK-1 and -2 phosphorylation at 24, 48, and 72 h after siRNA-mediated knockdown of APP in NSCLC cell lines A549 and H1299 (Fig. 3A, H1299 results). This supports the findings that APP can activate Ras (Russo et al., 2002). During an observation period of 72 h post siRNA transfection, downregulation of APP did not affect Akt phosphorylation at either T308 or S473 in any cell line tested (Fig. 3B,C, H1299 results). Although phosphorylation of 4E-BP1 at T37/46 is thought to be dependent on mTORC-1 activity, S65 and T70 residues are targeted by additional kinases, including cyclin-dependent kinase 1 (CDK-1) (Heesom et al., 2001) and ERKs (Herbert et al., 2002). We determined that APP downregulation caused reduced ERKs activation (Fig. 3A) and reduced CDK activity (to be published elsewhere). To address a possible role of these kinases, we performed experiments using the CDK-1 and MAP-kinase inhibitors roscovitine and UO126, respectively. We determined that neither kinase was exclusively involved in the 4E-BP1 phosphorylation pattern exhibited upon APP downregulation (Fig. 3D,E). Their inhibition may contribute to the phosphorylation status of S65, but do not explain the enhanced phosphorylation at T37/46. These results, alongside APP regulation of ERKs activity, support the idea that the effects seen on 4E-BP1 upon APP depletion may be mediated by multiple kinases. This is in keeping with the highly pleiotropic effects described for APP signaling.

APP seems to affect 4E-BP1 phosphorylation at T37/46 through transcriptional regulation of Styx

A number of results did not support the notion that APP could regulate 4E-BP1 phosphorylation at T37/46 through modulation of mTORC-1 (see below). Hence, we started investigating alternative mechanisms, including transcriptional regulation of possible mediators. APP can regulate transcription alongside Fe65 (which is recruited on the plasma...
membrane by full-length APP). Upon γ-secretase cleavage, Fe65 is associated to AICD and seems to protect free AICD from proteolytic degradation. It has been proposed that this complex can translocate to the nucleus where it regulates transcription alongside the factor Tip60 (Cao and Südhof, 2004). To identify putative genes that could possibly mediate APP effects on the 4E-BP1 phosphorylation pattern, we performed gene expression arrays using the Illumina HumanHT12 (48,000 probes, RefSeq plus EST). Cell lines H1299 and A549 were transfected with either a control siRNA, siRNA to APP or mock-transfected. Three independent experiments were performed in duplicate, total RNA was extracted from cells, and then labeled and hybridized to the Illumina chips. We found a number of genes, which expression was modified in both cell lines in similar ways, alongside a large number of genes that appeared to be altered in one cell line only. We identified a total of 17 genes whose expression was either downregulated to at least 50% or upregulated two-folds or more upon APP depletion in both H1299 and A549 cells. These modifications in expression were confirmed by individual Q-PCR experiments (Supplementary Fig. S1). We artificially downregulated the expression of all genes for which commercial siRNAs were available (boxed in blue in Supplementary Fig. S1A) and tested whether artificial down-regulation of these genes affected 4E-BP1 phosphorylation at T37/46 without affecting other critical 4E-BP1 residues’ phosphorylation sites (Fig. 3G). To provide additional evidence supporting a role for APP transcriptional regulation of Styx, we transfected H1299 and A549 cells with APP 695 cloned in pCAX vector (and used the empty vector as the negative control). APP forced expression alone increased the Styx mRNA expression level 1.6 fold (Fig. 3H). Thus, APP forced expression produced opposite effects compared to APP downregulation. To further confirm the link between APP regulation of Styx and the effects operated by Styx on the phosphorylation status of T37/46, we transfected H1299 cells with a variety of nucleic acids (Fig. 3I). Downregulation of either APP or Styx individually increased T37/46 phosphorylation to approximately similar levels. Simultaneous depletion of both APP and Styx produced additive effects on T37/46 phosphorylation (compare lanes 1 through 4). As expected, forced expression of AICD reduced 4E-BP1 phosphorylation level when compared to cells transfected with control plasmid (compare lanes 5 and 6). Co-transfection of control plasmid and siRNA to Styx enhanced T37/46 phosphorylation, while co-transfection of AICD alongside siRNA to Styx partially reversed this effect (lanes 7 and 8). Taken altogether, these results reinforced the link between the regulation of Styx by APP and the enhancement of phosphorylation of 4E-BP1 at the T37/46 residues (upon Styx depletion). We attempted to confirm variation of the Styx protein using Western blot assays; however, available commercial antibodies raised against Styx phosphorylation at T37/46 without affecting other critical 4E-BP1 residues’ phosphorylation sites (Fig. 3G). To provide additional evidence supporting a role for APP transcriptional regulation of Styx, we transfected H1299 and A549 cells with APP 695 cloned in pCAX vector (and used the empty vector as the negative control). APP forced expression alone increased the Styx mRNA expression level 1.6 fold (Fig. 3H). Thus, APP forced expression produced opposite effects compared to APP downregulation. To further confirm the link between APP regulation of Styx and the effects operated by Styx on the phosphorylation status of T37/46, we transfected H1299 cells with a variety of nucleic acids (Fig. 3I). Downregulation of either APP or Styx individually increased T37/46 phosphorylation to approximately similar levels. Simultaneous depletion of both APP and Styx produced additive effects on T37/46 phosphorylation (compare lanes 1 through 4). As expected, forced expression of AICD reduced 4E-BP1 phosphorylation level when compared to cells transfected with control plasmid (compare lanes 5 and 6). Co-transfection of control plasmid and siRNA to Styx enhanced T37/46 phosphorylation, while co-transfection of AICD alongside siRNA to Styx partially reversed this effect (lanes 7 and 8). Taken altogether, these results reinforced the link between the regulation of Styx by APP and the enhancement of phosphorylation of 4E-BP1 at the T37/46 residues (upon Styx depletion). We attempted to confirm variation of the Styx protein using Western blot assays; however, available commercial antibodies raised against Styx phosphorylation at T37/46 without affecting other critical 4E-BP1 residues’ phosphorylation sites (Fig. 3G). To provide additional evidence supporting a role for APP transcriptional regulation of Styx, we transfected H1299 and A549 cells with APP 695 cloned in pCAX vector (and used the empty vector as the negative control). APP forced expression alone increased the Styx mRNA expression level 1.6 fold (Fig. 3H). Thus, APP forced expression produced opposite effects compared to APP downregulation. To further confirm the link between APP regulation of Styx and the effects operated by Styx on the phosphorylation status of T37/46, we transfected H1299 cells with a variety of nucleic acids (Fig. 3I). Downregulation of either APP or Styx individually increased T37/46 phosphorylation to approximately similar levels. Simultaneous depletion of both APP and Styx produced additive effects on T37/46 phosphorylation (compare lanes 1 through 4). As expected, forced expression of AICD reduced 4E-BP1 phosphorylation level when compared to cells transfected with control plasmid (compare lanes 5 and 6). Co-transfection of control plasmid and siRNA to Styx enhanced T37/46 phosphorylation, while co-transfection of AICD alongside siRNA to Styx partially reversed this effect (lanes 7 and 8). Taken altogether, these results reinforced the link between the regulation of Styx by APP and the enhancement of phosphorylation of 4E-BP1 at the T37/46 residues (upon Styx depletion). We attempted to confirm variation of the Styx protein using Western blot assays; however, available commercial antibodies raised against Styx...
seemed unable to identify the endogenous protein. Considering all this evidence, we concluded that APP regulates the phosphorylation status of 4E-BP1 T37/46 through Styx (which is a poorly investigated protein) rather than primarily acting alongside the canonical PI3K/Akt/mTORC-1 axis (see below for further evidence concerning APP independence from mTORC-1). 4E-BP1 is an important node where the activity of different kinases and phosphatases converge to regulate cell growth (She et al., 2010).

APP depletion causes modifications of eIF-4F’s composition on the mRNA cap

We then asked whether the changes in the 4E-BP1 phosphorylation pattern corresponded to changes in the translation initiation complex on the mRNA cap. We tested this using a 7-methylguanosine conjugated resin pull-down. After APP downregulation, the most noticeable effect we observed was a more than eightfold increase (as determined by densitometry) in S’-cap-bound eIF-4A. All other major eIF-4F components showed no significant changes upon APP depletion, while the amounts of S’ cap-associated 4E-BP1 showed a 50% reduction (Fig. 4A). Reduced 4E-BP1 binding to the cap is a common indication of possible increased cap-dependent protein synthesis initiation (Thoreen et al., 2012). To confirm that APP depletion specifically affected eIF-4A functions in eIF-4F complexes, we used silvestrol in incorporation assays of the methionine surrogate L-azidohomoalanine (AHA) followed by FACS analysis. Silverstrol is an antibiotic that prevents eIF-4A binding to initiation complexes, hence inhibiting protein synthesis initiation (Bordeleau et al., 2008). Cells with depleted APP showed a certain resistance to both completely and partially inhibiting concentrations of silverstrol (Fig. 4B,C, respectively), thus confirming that APP may affect initiation complexes mainly by altering the binding of eIF-4A to eIF-4F
complexes. This result was further confirmed by the use of homoharringtonine, an antibiotic that inhibits protein synthesis elongation (Tujebejova et al., 1989). Homoharringtonine completely inhibited methionine analog (AHA) incorporation irrespective of APP depletion, yielding fluorescence readings virtually identical to no AHA incorporation (Fig. 4B).

**APP depletion increases the rate of global protein synthesis**

The above results suggested that APP regulates eIF-4F composition, and that it could potentially affect global protein synthesis. To explore this possibility, we measured the rate of protein synthesis in cells transfected with siRNA targeting APP compared to cells transfected with a control siRNA. Cells with depleted APP showed a 27% to 172% increase in fluorescent AHA incorporation compared to controls in different experiments performed in several NSCLC cell lines (Fig. 5A, B and Table 1). Similar results were obtained in a mesothelioma cell line (ME16), in immortalized human keratinocytes (HaCat) and in primary human lung fibroblasts (WI-38) (Supplementary Fig. S2). This increased protein synthesis rate was similar to what was obtained after insulin-treatment of cells maintained in 1% FBS overnight (Supplementary Fig. S3). We wanted to ascertain whether this increase in the rate of global protein synthesis was specific to cap-dependent translation. We used a bicistronic mRNA in which Renilla luciferase is translated using a cap-dependent mechanism, while firefly luciferase is translated using the poliovirus internal ribosome entry sequence (IRES), both encoded by a reporter plasmid. Multiple experiments in different cell lines (A549, H1299, and H1650) showed that both cap- and IRES-mediated protein translation was enhanced upon APP downregulation (Fig. 5C). This result is not unexpected if APP mainly regulates eIF-4A functions, since this factor is also heavily involved in IRES-dependent translation initiation (Komar and Hatzoglou, 2011).

**APP affects protein synthesis independently of mTORC-1**

The rate of global protein translation is primarily regulated by mTORC-1 activity. APP depletion caused increased phosphorylation of 4E-BP1 at T37/46, two mTORC-1 targets. However, increased APP-dependent phosphorylation at T37/46 appeared to be mediated by Styx, a pseudophosphatase not linked in any way to mTORC-1 function. To clarify whether APP effects on protein synthesis were dependent or related to mTORC-1 activity, we further explored the mTORC-1 signaling pathway. Surprisingly, APP downregulation did not affect other key markers of mTORC-1 activation, those being phosphorylation of p70S6 kinase or its target small ribosomal subunit protein S6 (Fig. 5D). This observation caused us to doubt the existence of a link between APP effects and mTORC-1 activity. To further elucidate whether mTOR played a role in the observed increase in the global protein synthesis rate upon APP downregulation, we used Torin-1, a potent and selective mTOR inhibitor (Thoreen et al., 2012). A number of experiments performed on different NSCLC cell lines confirmed that Torin-1 is a very potent suppressor of global protein translation (Fig. 5E). Forty-eight hours of Torin-1 treatment suppressed 4E-BP1 and S6 kinase phosphorylation, while AHA incorporation was virtually abolished (Fig. 5E). However, the effects of APP downregulation on protein synthesis did not appear to be dependent on mTOR activity (Fig. 5F, Table 1, and Supplementary Fig. S4), since Torin-1-treated, APP-depleted NSCLC cells still displayed a conspicuous increase in methionine-analog incorporation compared to the relevant controls.

Overexpression of AICD caused a decrease in AHA incorporation (Fig. 5G), opposite to the effect of APP depletion. These opposing results indicate that the levels of APP control the global rate of protein synthesis. Moreover, this effect appears to be independent of mTOR functions. Increased...
IRES-driven translation further supports a main role for eIF-4A in this process over regulation of eIF-4E binding to the cap (the central step in protein synthesis initiation regulated by mTORC-1).

A recent study suggested that the APP fragment Aβ stimulates mTORC-1 activity via PRAS40 phosphorylation (Caccamo et al., 2011). We observed a modest increase in PRAS40 phosphorylation upon APP depletion (Supplementary Fig. S5A). To further explore this phenomenon in coimmunofluorescence experiments, we also observed APP and phosphoproteins in total cell lysates obtained from H1299 cells treated with DMSO (c), or with Torin-1, right, AHA incorporation in H1299 cells transfected with a control siRNA and exposed to DMSO (red), transfected with siRNA to APP and exposed to DMSO (blue), transfected with a control siRNA and exposed to Torin-1 (light green), and transfected with siRNA to APP and exposed to Torin-1 (light brown). G: AHA incorporation in H1299 cells transfected with pCDNA3 (c) or with AICD cloned in pCDNA3 (AICD). All nucleic acids were transfected by electroporation. Note that cells electroporated with plasmid DNA appear to incorporate substantially less AHA compared to cells electroporated with siRNAs only.

Finally, in parallel control experiments, we performed siRNA to the APP family protein APLP-2, which shares the localization to the Golgi was lost and became similar to that of mTOR (Supplementary Fig. S5D). To investigate whether APP interacted with mTORC-1, we performed a number of coimmunoprecipitation experiments and consistently failed to detect APP or its fragments in association with RAPTOR (not shown). Furthermore, APP depletion did not affect the expression levels of either RAPTOR or mTOR (Supplementary Fig. S5A). This evidence led us to conclude that APP likely does not affect mTORC-1 functions through PRAS40 phosphorylation. This potential contribution seemed tenuous and mechanistically problematic in order to address the phenotype observed on global protein synthesis, which seems independent of mTORC-1.
highest degree of sequence homology and tissue distribution compared to APP. Although siRNA to APLP-2 was effective and specific, APLP-2 depletion did not affect the rate of protein synthesis of tested cells (Supplementary Fig. S6). Hence, it appears that what we describe here is specific to APP and not to APLP-2.

**Discussion**

We described that APP depletion causes a rearrangement in the 4E-BP1 phosphorylation pattern and enhances eIF-4A recruitment within eIF-4F complexes on the cap. This is paralleled by a substantial increase in the rate of global protein synthesis in a variety of human dividing cells, cancerous and normal.

We presented data using GSI because they provide additional confirmatory evidence in support of the experiments involving APP downregulation. However, results obtained with GSIs can only be indicative, since γ-secretase complexes cleave a plethora of different substrates (to date, 91 proteins have been identified as substrates for γ-secretase cleavage; Hemmig et al., 2008; McCarthy et al., 2009).

APP seems to affect 4E-BP1 phosphorylation primarily through its AICD, due to its transcriptional regulation of Styx. This pseudophosphatase has the potential to affect different proteins/pathways, including ERKs (Reiterer et al., 2013), PTPMP1 (Niemi et al., 2014) and Ras signaling through interaction with G3BP-I (Barr et al., 2013). Downregulation of Styx caused an increase in 4E-BP1 phosphorylation at T37/46, similarly to what was observed after APP depletion. We propose that the results observed concerning 4E-BP1 phosphorylation are likely the result of modified activities of multiple kinases/phosphatases, which include ERKs in concert with Styx (Fig. 6).

Albeit apparently non-canonical, the changes in the 4E-BP1 phosphorylation pattern were paralleled by a 50% decreased recruitment of this protein on the cap. This event is an indication of increased cap-dependent translation (She et al., 2010; Thoreen et al., 2012). Our data support the idea that APP influences translation primarily by affecting the efficiency of eIF-4A association with initiation complexes. This is supported by a number of observations including: (i) increased eIF-4A binding to the cap; (ii) cells with depleted APP show resistance to silvestrol; and (iii) the measured increase of both cap- and IRES-dependent protein translation. eIF-4A is a central initiation factor involved in the unwinding of secondary structures of probably all mRNAs (Schütz et al., 2008); therefore, eIF-4A appears to be the main eIF-4F subunit that can enhance both cap- and IRES-driven translation.

APP depletion caused an increase in the global rate of protein synthesis quantitatively similar to what was elicited by insulin stimulation of serum-starved cells. We hence propose that the effects mediated by APP on protein synthesis are mTORC-1 independent. We used Torin-1 instead of rapamycin, since it is well known that prolonged rapamycin exposure can cause compensatory responses that are mechanistically difficult to explain (Sarbassov et al., 2006; Choo et al., 2008; Thoreen et al., 2012). Torin-1 completely inhibited mTORC-1 activity, virtually abolished AHA incorporation, and led to the death of about one third of exposed cells within 48 h (not shown). Despite the harsh inhibitory conditions, APP downregulation caused increased AHA incorporation. Evidence suggesting that APP operates independently of mTORC-1 are as follows: (i) APP downregulation did not modify the phosphorylation state of p70S6 kinase or its downstream target S6; (ii) APP depletion did not yield any modification in the mTOR/RAPTOR ratio; (iii) APP depletion had no effect on Akt phosphorylation at either T308 or S473; and (iv) we failed to find any association of APP to mTORC-1 complexes (not shown). In support of previous studies (Caccamo et al., 2011), we found that APP depletion caused a modest increase of PRAS40 phosphorylation. PRAS40 has been proposed as an mTORC-1 inhibitor, which, upon Akt phosphorylation at T246, activates mTORC-1 (Sancak et al., 2007). However, recent studies have revealed that the PRAS40 effects are highly context-dependent (Pallares-Cartes et al., 2012). The data obtained here do not suggest a major role for PRAS40 for two reasons: (i) the increase in phosphorylation at T246 appears to be very modest; and (ii) APP, before depletion, seems to co-localize with PRAS40 in the Golgi apparatus, while mTOR seems uniformly distributed throughout the cytoplasm. Upon APP depletion, the expression levels of PRAS40 are unchanged, but PRAS40 distribution is more similar to that of mTOR. Therefore, it is quite problematic
to reconcile the release of a putative inhibitor with mTORC-1 activation, unless PRAS40 is an mTORC-1 stimulator in our system. This needs to be clarified in further studies. In any case, if PRAS40 contributes to mTORC-1 activation, it should be confined only to its ability to phosphorylate 4E-BP1 at T37/46 and not p70S6K.

The phenotypes described here are dependent on the APP’s AICD, since forced expression of it reverses the effects of APP depletion. APP has been extensively studied in recent decades. Overall, a complex network of interactions with both extracellular and intracellular proteins has emerged (Müller et al., 2013). Several roles for AICD have been described, including its interaction with more than 20 cellular proteins. AICD instability has hampered a unifying interpretation of its function(s). Understanding the AICD binding partner(s) responsible for the phenomena presented here goes beyond the scope of this investigation and represents a future direction of our research. Nonetheless, our data suggest an active role of cleaved AICD. γ-secretase cleavage inhibition phenotypes seemed to be mirrored by APP depletion, while APP-depletion-derived phenotypes were reversed by AICD overexpression.

In summary, we propose a model suggesting two phenomena: (i) AICD regulates global translation through modulation of eIF-4A and possibly 4E-BP1 phosphorylation; and (ii) loss of function of AICD results in uncontrolled increase in global protein synthesis. Whether AICD regulates protein synthesis in post-mitotic cells (such as mature neurons) remains to be established.

Acknowledgments

We thank Patricia Simms for invaluable help with FACS experiments. We thank Dr. Clodia Osipo and Dr. Lucio Miele for critical reading of the manuscript.

Literature Cited

Bachmar A, Finley D, Varshavsky A. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234:179–186.

Barb J, Mynulty MR, Frazier EA, Hinton SD. 2013. The pseudophosphatase MK-STYX inhibits stress granule assembly independently of Ser14 phosphorylation of G3BP-1. J Biol Chem 288:2373–2384.

Becquet C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickel R, Rieger-Escarra J, Oldham S, Brugolo W, Stocker H, Andruss BF, Beckingham K, Bachmair A, Finley D, Varshavsky A. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234:179–186.

Bickel R, Rieger-Escarra J, Oldham S, Brugolo W, Stocker H, Andruss BF, Beckingham K, Bachmair A, Finley D, Varshavsky A. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234:179–186.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickel R, Rieger-Escarra J, Oldham S, Brugolo W, Stocker H, Andruss BF, Beckingham K, Bachmair A, Finley D, Varshavsky A. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234:179–186.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.

Bickeblit C, Naivea NN, Belayev ND, Turner AJ. 2012. Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24:402–409.
Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. 2012. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485:109–113.

Tujebajeva RM, Graifer DM, Karpova GG, Ajtkhozhina NA. 1989. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett 257:254–256.

Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, Griffin JD, Bernstein ID. 2000. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci 113:4313–4318.

Villalonga P, Fernández de Mattos, Ridley S. 2009. RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation. J Biol Chem 284:35287–35296.

Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W, Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W, Pandey PR, Fukuoka K, Hirota S, Sugii T, Wakabayashi G, Koeda K, Kashiwaba M, Suzuki K, Chiba T, Endo M, Mo YY, Watabe K. 2011. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 30:4075–4086.

Yvon ES, Vigouroux S, Rousseau RF, Biagi E, Amrolia P, Dotti G, Wagner HJ, Brenner MK. 2003. Overexpression of the Notch ligand, Jagged-1, induces alleloantigen-specific human regulatory T cells. Blood 102:3815–3821.

Zou J, Li P, Lu F, Liu N, Du J, Ye J, Qu X, Sun X, Ma D, Park J, Ji C. 2013. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol 6:3.

Supporting Information
Additional supporting information may be found in the online version of this article.